Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17262920 | 0.80 | — | — | |
| SCHEMBL7666526 | 0.71 | MAPK1 (0.34) | — | |
| SCHEMBL8555632 | 0.69 | — | — | |
| SCHEMBL13735624 | 0.69 | TSHR (0.39) | SUCNR1KDM4EGMNNLMNAPMP22 | |
| SCHEMBL5584855 | 0.69 | — | — | |
| SCHEMBL10701438 | 0.67 | KDM4E (0.42) | SUCNR1KDM4EGMNNLMNAPMP22 | |
| SCHEMBL1602564 | 0.65 | — | — | |
| SCHEMBL13795024 | 0.64 | KDM4E (0.44) | KDM4EGMNNLMNAPMP22TFPI2 | |
| SCHEMBL8067270 | 0.64 | KDM4E (0.44) | KDM4EGMNNLMNAPMP22TFPI2 | |
| SCHEMBL4738727 | 0.64 | KDM4E (0.44) | KDM4EGMNNLMNAPMP22TFPI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3651762-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3634967-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | Novartis AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| WO-2019014427-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2018225009-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2018-12-13 | — | — | WO | disclosed |
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | disclosed |
| EP-2129224-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-2086534-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | Genetic Technologies Limited (AU) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008124450-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008058342-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | PPP1R10, TASP1, PPP5C | SUCNR1 2025/4885KDM4E 1897/4885GMNN 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.